Education and Training
MD - SUNY Upstate Medical University, Syracuse, NY
Medicine - Children’s Hospital of Philadelphia, Philadelphia, PA
Medicine - Children’s Hospital of Philadelphia, Philadelphia, PA
Pediatric Bone Marrow Transplant & Immunotherapy - Children’s Hospital of Philadelphia, Philadelphia, PA
Pediatric Hematology/Oncology - Children’s Hospital of Philadelphia, Philadelphia, PA
Pediatric Hospital Epidemiology and Outcomes Research Training Program - Children’s Hospital of Philadelphia, Philadelphia, PA
Pediatric Hematology-Oncology – American Board of PediatricsPediatrics – American Board of Pediatrics
MSCE - University of Pennsylvania, Philadelphia, PA
MA in Biological Sciences - Hunter College of the City of New York, New York, NY
Titles and Academic Titles
Richard & Sheila Sanford Endowed Chair in Pediatric Oncology
Assistant Professor, Perelman School of Medicine at the University of Pennsylvania
Departments and Services
Allison Barz Leahy, Yimei Li, Julie-An Talano, Caitlin W Elgarten, Alix E Seif, Yongping Wang, Bryon Johnson, Dimitri S Monos, Stephan Kadauke, Timothy S Olson, Jason Freedman, Lisa Wray, Stephan A Grupp, Nancy Bunin: Unrelated donor a/b T-cell and B-cell-depleted HSCT for the treatment of pediatric acute leukemia. Blood Advances 6(4): 1175-1185, Feb 2022.
Diorio C, Shraim R, Myers R, Behrens EM, Canna S, Bassiri H, Aplenc R, Burudpakdee C, Chen F, DiNofia AM, Gill S, Gonzalez V, Lambert MP, Leahy AB, Levine BL, Lindell RB, Maude SL, Melenhorst JJ, Newman H, Perazzelli J, Seif AE, Lacey SF, June CH, Barrett DM, Grupp SA, Teachey DT.: Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. Clin Cancer Res 28: 3804-3813, Sep 2022.
Li Y, Hwang WT, Maude SL, Teachey DT, Frey NV, Myers RM, Barz Leahy A, Liu H, Porter DL, Grupp SA, Shaw PA.: Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies. Clin Cancer Res 28: 3940-3949, Sep 2022.
Reeve BB, Hernandez A, Freyer DR, Linder LA, Embry L, Leahy AB, Baker JN, Mack JW, McFatrich M, Henke DM, Mowbray C, Jacobs SS, Maurer SH, Gold SH, Hinds PS.: Capturing the young child's reports of cancer treatment tolerability: Does our practice reflect an assumption that they cannot report? Pediatr Blood Cancer Oct 2022.
Newman H, Li Y, Liu H, Myers RM, Tam V, DiNofia A, Wray L, Rheingold SR, Callahan C, White C, Baniewicz D, Winestone LE, Kadauke S, Diorio C, June CH, Getz K, Aplenc R, Teachey DT, Maude SL, Grupp SA, Bona K, Barz Leahy A.: Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Blood Nov 2022.
Stephan Kadauke, Regina M Myers, Yimei Li, Richard Aplenc, Diane Baniewicz, David M Barrett, Allison Barz Leahy, Colleen Callahan, Joseph G Dolan, Julie C Fitzgerald, Whitney Gladney, Simon F Lacey, Hongyan Liu, Shannon L Maude, Regina McGuire, Laura S Motley, David T Teachey, Gerald B Wertheim, Lisa Wray, Amanda M DiNofia, Stephan A Grupp: Risk Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol 39(8): 920-930, March 2021.
Allison Barz Leahy, Kaitlin J Devine, Yimei Li, Hongyan Liu, Regina Myers, Amanda DiNofia, Lisa Wray, Susan R Rheingold, Colleen Callahan, Diane Baniewicz, Maria Patino, Haley Newman, Stephen P Hunger, Stephan A Grupp, David M Barrett, Shannon L Maude: Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T cell therapy. Blood 139(14): 2173-2185, May 2021.
Shalabi H, Gust J, Taraseviciute A, Wolters PL, Leahy AB, Sandi C, Theodore W Laetsch, Lori Wiener, Rebecca A Gardner, Veronique Nussenblatt, Joshua A Hill, Kevin J Curran, Timothy S Olson, Colleen Annesley, Hao-Wei Wang, Javed Khan, Marcelo C Pasquini, Christine N Duncan, Stephan A Grupp, Michael A Pulsipher, Nirali N Shah: Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells. Nat Rev Clin Oncol. 18(6): 363-378, June 2021.
Barz Leahy A, Li Y, Talano J, Elgarten CW, Seif AE, Alix E Seif, Yongping Wang, Bryon Johnson, Dimitri S Monos, Stephan Kadauke, Timothy S Olson, Jason Freedman, Lisa Wray, Stephan A Grupp, Nancy Bunin: Unrelated donor a/b T-cell and B-cell-depleted HSCT for the treatment of pediatric acute leukemia. Blood Advances 6(4): 1175-1185, July 2021.
Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Christina C Fasano, Susan R Rheingold, Amanda DiNofia, Lisa Wray, Richard Aplenc, Diane Baniewicz, Hongyan Liu, Pamela A Shaw, Edward Pequignot, Kelly D Getz, Jennifer L Brogdon, Andrew D Fesnak, Donald L Siegel, Megan M Davis, Chelsie Bartoszek, Simon F Lacey, Elizabeth O Hexner, Anne Chew, Gerald B Wertheim, Bruce L Levine, Carl H June, Stephan A Grupp, Shannon L Maude: Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. J Clin Oncol 39(27): 3044-3055, Sep 2021.
Barz Leahy A, Newman H, Li Y, Liu H, Myers R, Dinofia A, Joseph G Dolan, Colleen Callahan, Diane Baniewicz, Kaitlin Devine, Lisa Wray, Richard Aplenc, Carl H June, Stephan A Grupp, Susan R Rheingold, Shannon L Maude: CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol. Lancet Haematol 8(10): e711-e722, October 2021.
Leahy AB, Stanley K, Myers R, Dinofia A, Wray L, Rheingold SR, Colleen Callahan, Diane Baniewicz, Maria Patino, Haley Newman, Stephen P Hunger, Stephan A Grupp, David M Barrett, Shannon L Maude: Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T cell therapy. Blood 139(14): 2173-2185, Dec 2021.
McFatrich M, Brondon J, Lucas NR, Hinds PS, Maurer SH, Mack JW, Freyer DR, Jacobs SS, Baker JN, Mowbray C, Wang M, Castellino SM, Barz Leahy A, Reeve BB.: Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research. Cancer 126(1): 140-147, Jan 2020.
Hill D, Leahy AB, Sciasci J, O'Neill S, Reilly A, Balamuth N, Seeholzer S, Spergel J, Brown-Whitehorn T: Medication contaminants as a potential cause of anaphylaxis to vincristine. Pediatr Blood Cancer 65(1): 10.1002, Jan 2018.
Phillips C, Leahy AB, Li Y, Schapira M, Bailey C, Merchant R.: Googling cancer: the relationship between state-level online search volume and cancer incidence. J Med Internet Res. 10(1): e6, Jan 2018.
Getz K, Sung L, Ky B, Gerbing R, Leger K, Leahy AB, Sack L, Woods W, Alonzo T, Gamis A, Aplenc R.: Occurrence of Treatment-Related Cardiotoxicity and its Impact on Outcomes among Children Treated on the AAML0531 Clinical Trial: A Report from the Children's Oncology Group. JCO Page: 12-21, January 2019.
Hill D, Leahy AB, Sciasci J, O’Neill S, Reilly A, Balamuth N, Seeholzer S, Spergel J, Brown-Whitehorn T. Medication contaminants as a potential cause of anaphylaxis to vincristine. Pediatr Blood Cancer. 2017 Aug 22. Epub ahead of print.
Basch E, Deal A, Kris MG, Scher H, Hudis C, Sabbatini P, Rogak L, Bennett A, Dueck A, Atkinson T, Chou J, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan J, Schrag D. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol. 2016 Feb 20; 34(6):557-65.
Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014 Sep 29;106(9)
Judson TJ, Bennett AV, Rogak LJ, Sit L, Barz A, et al. Feasibility of Long-Term Patient Self- Reporting of Toxicities From Home via the Internet During Routine Chemotherapy. J Clin Oncol. 2013 Jul 10;31(20):2580-5.
Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris M, Schrag D. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. Journal of the National Cancer Institute. 2009 Dec 101(23): 1624-1632.
Basch E, Iasonos A, Barz A, Culkin A, Kris M, Artz D, Fearn P, Speakman J, Scher H, McCabe M, Schrag D. Online symptom self-reporting by lung cancer patients using the Common Terminology Criteria for Adverse Events (CTCAE). Journal of Clinical Oncology. 2007 Dec 25(34): 5374-80.
Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K, Pun C, Yong H, Fearn P, Barz A, Scher H, McCabe M, Schrag D. Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. Journal of the American Medical Informatics Association. 2007 May 14(3): 264-268.
Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. The Lancet Oncology. 2006 Nov 7(11): 883-4.
Berwick M, Orlow I, Mahabir S, Myskowski P, Coit D, Brady M, Roy P, Song Y, Canchola R, Barz A, Bolognia J, Eng S, Elahi A, Begg CB. Estimating the relative risk of developing melanoma in INK4A carriers. European Journal of Cancer Prevention. 2004 Feb 13(1): 65- 70.
Orlow I, Roy P, Barz A, Canchola R, Song Y, Berwick M. Validation of denaturing high performance liquid chromatograph as a rapid detection method for the identification of human INK4A gene mutations. Journal of Molecular Diagnostics. 2001 Nov 3(4): 158-63.
Getz K, Sung L, Ky B, Gerbing R, Leger K, Leahy AB, Sack L, Woods W, Alonzo T, Gamis A, Aplenc R. Incidence and Predictors of Anthracycline Cardiotoxicity among Children Treated on the AAML0531 Clinical Trial: A Report from the Children’s Oncology Group. Submitted to ASH Annual Meeting 2017.
Posters and Presentations
Myers R, Devine K, Li Y, Lawrence S, Barz Leahy A, Liu H: Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Oral presentation, American Society of Hematology Annual Meeting, Atlanta, GA 2021.
Ceolin V, Brivio E, Rheingold S, Leahy AB, Vormoor B, O'Brien M: Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia. Poster presentation, American Society of Hematology Annual Meeting, Atlanta, GA 2021.
Diorio C, Shraim R, Myers R, Burudpakdee C, Barz Leahy A, Aplenc R: Comprehensive Secretome Profiling Elucidates Novel Disease Biology and Identifies Pre-Infusion Candidate Biomarkers to Predict the Development of Severe Cytokine Release Syndrome in Pediatric Patients Receiving CART19. Oral presentation, American Society of Hematology Annual Meeting, Atlanta, GA 2021.
Lerman B, Li Y, Liu H, Myers R, Devine K, Callahan C, Baniewicz D, Kadauke Sm DiNofia A, Rheingold S, Wray L, Aplenc R, Grupp S, Maude S, Barz Leahy A.: Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL. Poster presentation, American Society of Hematology Annual Meeting, Atlanta, GA 2021.
Myers RM, Fitzgerald JC, Dinofia AM, Wray L, Leahy AB, Li Y, Smith L, Burrows E, Ramos M, Motley L, Khan R, Getz KD, Aplenc R, Grupp S, Maude SL: Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019. Oral presentation, American Society of Hematology Annual Meeting, Orlando, FL 2019.
Leahy AB, Stanley K, Myers R, Dinofia A, Wray L, Rheingold SR: Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy. Blood 134(Supplement 1), 2019 Notes: doi: 10.1182/blood-2019-130060.
Leahy AB, Helton G, Scholes D, Jurgielewicz A, Reeve BB, Schwartz L, Aplenc R, Basch E: Pediatric Patient-Reported Symptom Tracking in Oncology (Pedi-PReSTO): A Feasibility Study. Poster presentation, American Society of Hematology Annual Meeting 2018.
Leahy AB, Elgarten C, Li Y, Huang Y-S, Fisher BT, Delp D, Aplenc R, Getz K. : Evaluation of Hospital Admission Patterns in Children Receiving Treatment for Acute Lymphoblastic Leukemia: what does a typical leukemia experience look like? Poster presentation, American Society of Hematology Annual Meeting 2018.
Leahy AB, Scholes D, Helton G, Reeve BB, Schwartz L, Aplenc R, Basch E. : Symptom monitoring using patient-reported outcome (PRO) instruments in pediatric oncology patients hospitalized for chemotherapy: A feasibility study. Oral presentation, International Society for Quality of Life (ISOQOL) Annual Meeting October 2018.
Leahy AB. Invited speaker, "What do the kids say? PROs and clinical decision-making in pediatric oncology" St. Jude Research Seminar, Webinar. Nov 2021.
Leahy AB. "Patient-reported Symptom Tracking in Oncology: Who is it for? What do we know?" Texas Adolescent and Young Adult Oncology Annual Conference, Webinar. Feb 2021.
Leahy AB. Invited Panelist for "Enhancing the Patient Journey through Evidence Generation," within Building a Policy Framework for Cell Therapies hosted by the Duke-Margolis Center for Health Policy, Webinar. Oct 2020.
Leahy AB. "Can kids monitor their own symptoms? Pediatric patient-reported symptom tracking in oncology." Symposium: Patient-reported Outcomes in Drug Development & Clinical Practice. American College of Clinical Pharmacology Annual Meeting, Webinar. Sept 2020.
Leahy AB. Session Chair, "CAR T cells and PROs: What should be used?" CAR T-Cell Therapy: Beyond the Storm Virtual Meeting. NIH/NCI, Webinar. May 2020.
Leahy AB. "Can kids monitor their own symptoms? Pediatric patient-reported symptom tracking in oncology." PHO Research Conference, University of Michigan Division of Pediatric Hematology/Oncology, Ann Arbor, MI. Mar 2020.
Leahy AB. "Integrating ,PROs into clinical care: Benefits and challenges." Accelerating Anticancer Agent Development and Validation Annual Workshop. Bethesda, MD. May 2019.
Awards and Honors
2017-2018, American Society of Hematology Clinical Research Training Program Fellow
2017-present, Recipient of NIH Loan Repayment Program in Pediatric Research
2017-2018, American Society of Hematology Clinical Research Training Program Fellow
2011, Dracker Family Scholarship
2011, Jack J. Schneider Scholarship
2011, Commendation, outstanding performance in clinical years, SUNY Upstate College of Medicine
2011, Gold Humanism Honor Society
2011, Alpha Omega Alpha
Editorial and Academic Positions
2021, Reviewer, JAMA Open
2021, Reviewer, Supportive Care
2020-present, Reviewer, JAMA Pediatrics
2019-present, Reviewer, BMJ Open
2018-present, Clinical Trials
2018-present, Pediatric Hematology and Oncology
2017-present, Supportive Care in Cancer
2017-present, Journal of Clinical Oncology
Academic and Institutional Committees
2016-present, Lead, Quality Improvement Project
2016-2018, Fellow Liaison, Pediatric Hematology/Oncology Fellowship
Leadership and Memberships
Memberships in Professional Organizations
2019-present, Multinational Association of Supportive Care in Cancer
2017-present, International Society for Quality of Life Research
2020-present, Center for International Blood & Marrow Transplant Research
2019-present, National Institutes of Health
-2019-present, CAR T-cell Therapy: Beyond the Storm Steering Committee
2019-present, Memorial Sloan-Kettering Cancer Center
- 2019-present, International PRO-AYA Expert Panel
2017-present, American College of Epidemiology
2017-present, American Society of Hematology
2016-present, American Society of Pediatric Hematology and Oncology
2015-present, Children’s Oncology Group
2014-present, American Society of Clinical Oncology
Patient Experience Ratings
About the Patient Experience Rating System
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.